Elena Sendagorta Cudos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Sendagorta Cudos has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Herranz Pinto
Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain
2 shared publications - Rosa A. Feltes Ochoa
Hospital Universitario La Paz Madrid Spain
2 shared publications - Alexander Forero-Torres
Hospital Universitario del Sureste, Ronda del Sur, 10, 28500 Arganda del Rey, Madrid, Spain
1 shared publication - Alfonso Cabello
Division of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1 shared publication - Almudena Nuño González
Department of Dermatology La Paz University Hospital Madrid Spain
1 shared publication - Ander Mayor Ibarguren
Servicio de Dermatología Hospital Universitario La Paz Madrid Spain
1 shared publication
Latest Publications
- 5 November 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 146, 106581
Anifrolumab for refractory dermatomyositis: Experience from a Spanish cohort
- 5 November 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 146, 106581
Anifrolumab for refractory dermatomyositis: Experience from a Spanish cohort
- 28 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (2) , 711-713
Positive predictive values of enzyme-linked immunosorbent assay (ELISA) for antienvoplakin and anticollagen VII antibodies: Results from 4 centers from Spain
- 28 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (2) , 711-713
Positive predictive values of enzyme-linked immunosorbent assay (ELISA) for antienvoplakin and anticollagen VII antibodies: Results from 4 centers from Spain
- Open Access
- 6 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (2) , e332-e342
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
Background: Men who have sex with men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infection. However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain sparse. Methods: This phase IV trial evaluated the immunogenicity, safety, and impact of age and CD4/CD8 ratio on 9vHPV vaccine responses in MSM with HIV up to 35 years. Inclusion criteria were age 16–35, undetectable viral load, and CD4 + counts >200 cells/mm³. Participants received 9vHPV vaccine doses at weeks 0, 8, and 24, and were followed to week 96. Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collected at baseline, week 28, and week 96. Additionally, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8 ratio. Results: Among 158 enrolled participants, 138 completed the per-protocol analysis. Seroconversion exceeded 85% for all nine HPV vaccine genotypes at week 96. New infections with vaccine-included genotypes occurred in 24% of participants, predominantly involving HPV-16. The overall clearance rate for any high-risk HPV genotype included in the vaccine was 74% at week 96. Neither older age (≥26 years), lower CD4/CD8 ratio, nadir CD4 or CD4 counts affected immunogenicity. No severe adverse events related to vaccination were recorded. Conclusions: The 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation. Clinical Trial Registration: EudraCT number 2018–000215-24.
- 6 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (2) , e332-e342
Open AccessA Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
Background: Men who have sex with men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infection. However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain sparse. Methods: This phase IV trial evaluated the immunogenicity, safety, and impact of age and CD4/CD8 ratio on 9vHPV vaccine responses in MSM with HIV up to 35 years. Inclusion criteria were age 16–35, undetectable viral load, and CD4 + counts >200 cells/mm³. Participants received 9vHPV vaccine doses at weeks 0, 8, and 24, and were followed to week 96. Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collected at baseline, week 28, and week 96. Additionally, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8 ratio. Results: Among 158 enrolled participants, 138 completed the per-protocol analysis. Seroconversion exceeded 85% for all nine HPV vaccine genotypes at week 96. New infections with vaccine-included genotypes occurred in 24% of participants, predominantly involving HPV-16. The overall clearance rate for any high-risk HPV genotype included in the vaccine was 74% at week 96. Neither older age (≥26 years), lower CD4/CD8 ratio, nadir CD4 or CD4 counts affected immunogenicity. No severe adverse events related to vaccination were recorded. Conclusions: The 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation. Clinical Trial Registration: EudraCT number 2018–000215-24.
- 9 November 2023
- Published by Edicions UIB
- Vol. 6 (2) , 11-16
ANORECTAL ULCERS DIFFERENTIAL DIAGNOSIS FOR GENERAL SURGEONS
Introducción. La patología perianal es frecuente entre la población de hombres que tienen sexo con hombres (HSH). A menudo se manifiesta en forma de úlceras anorrectales, cuyo diagnóstico diferencial es amplio y debe ser conocido para el cirujano general. Materiales y métodos. A partir de un caso, se ha realizado una revisión de la literatura. Se ha descrito la epidemiología y la etiología de los procesos ulcerativos en la región perianal en este grupo poblacional. Resultados. El abanico de enfermedades que producen úlceras anorrectales es amplio. La primera causa es infecciosa. Se debe descartar también la neoplasia anal, la enfermedad inflamatoria intestinal, y las neoplasias hematológicas, entre otros. Conclusión. Es preciso saber manejar las úlceras perianales y anorrectales. Un correcto diagnóstico diferencial permitirá administrar el tratamiento más oportuno a este grupo de enfermos.
- 9 November 2023
- Published by Edicions UIB
- Vol. 6 (2) , 11-16
ANORECTAL ULCERS DIFFERENTIAL DIAGNOSIS FOR GENERAL SURGEONS
Introducción. La patología perianal es frecuente entre la población de hombres que tienen sexo con hombres (HSH). A menudo se manifiesta en forma de úlceras anorrectales, cuyo diagnóstico diferencial es amplio y debe ser conocido para el cirujano general. Materiales y métodos. A partir de un caso, se ha realizado una revisión de la literatura. Se ha descrito la epidemiología y la etiología de los procesos ulcerativos en la región perianal en este grupo poblacional. Resultados. El abanico de enfermedades que producen úlceras anorrectales es amplio. La primera causa es infecciosa. Se debe descartar también la neoplasia anal, la enfermedad inflamatoria intestinal, y las neoplasias hematológicas, entre otros. Conclusión. Es preciso saber manejar las úlceras perianales y anorrectales. Un correcto diagnóstico diferencial permitirá administrar el tratamiento más oportuno a este grupo de enfermos.
- Open Access
- 26 December 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (1) , 92-100
Anal carcinoma diagnosed over a 20‐year period in a Spanish tertiary center: A retrospective analysis
Background: Anal cancer, although rare, is susceptible to early diagnosis. There is a group of patients who are at high risk for anal cancer, including immunocompromised individuals and particularly people living with human immunodeficiency virus (PLWH). In 2010, an anal cancer screening programme was implemented at the University Hospital La Paz (Hospital Universitario La Paz [HULP]) in Madrid, Spain, to diagnose and treat high‐grade squamous epithelial lesions (HSIL), which are the precursor to anal squamous cell carcinoma (ASCC).Objective: To describe the characteristics of patients with ASCC diagnosed during the last 20 years in a Spanish tertiary hospital, and to identify differences between those diagnosed before and after the screening programme was implemented.Methods: A retrospective, single‐centre study was conducted in a tertiary care centre. Clinical and demographic characteristics of patients diagnosed with squamous cell carcinoma of the anal or perianal canal between September 2000 and September 2020 at HULP were analysed.Results: Forty‐three patients diagnosed with ASCC were included; 55% of them were immunosuppressed and no differences were found in terms of the period distribution of these patients. In the second period, more cases of ASCC were diagnosed in PLWH, but they had a higher CD4(+) T cell nadir count. Although more T1–T2 tumours were observed in the second period studied, the difference in tumour size between periods was not statistically significant (p = 0.103). In 23% of patients, HSIL was present before diagnosis (median time to progression: 67.6 months). At the start of the screening programme, four patients in follow‐up were diagnosed with ASCC. In addition, five patients who were not in follow‐up (despite meeting the criteria of the screening programme) were also diagnosed, but at more advanced stages.Conclusions: During the last decade, the cases of ASCC diagnosed in our hospital have not decreased, likely due to the increasing global incidence of this disease, but also to the activity of our screening programme. Nevertheless, four PLWH included in the screening programme were diagnosed at earlier stages of the disease.
- 26 December 2022
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (1) , 92-100
Open AccessAnal carcinoma diagnosed over a 20‐year period in a Spanish tertiary center: A retrospective analysis
Background: Anal cancer, although rare, is susceptible to early diagnosis. There is a group of patients who are at high risk for anal cancer, including immunocompromised individuals and particularly people living with human immunodeficiency virus (PLWH). In 2010, an anal cancer screening programme was implemented at the University Hospital La Paz (Hospital Universitario La Paz [HULP]) in Madrid, Spain, to diagnose and treat high‐grade squamous epithelial lesions (HSIL), which are the precursor to anal squamous cell carcinoma (ASCC).Objective: To describe the characteristics of patients with ASCC diagnosed during the last 20 years in a Spanish tertiary hospital, and to identify differences between those diagnosed before and after the screening programme was implemented.Methods: A retrospective, single‐centre study was conducted in a tertiary care centre. Clinical and demographic characteristics of patients diagnosed with squamous cell carcinoma of the anal or perianal canal between September 2000 and September 2020 at HULP were analysed.Results: Forty‐three patients diagnosed with ASCC were included; 55% of them were immunosuppressed and no differences were found in terms of the period distribution of these patients. In the second period, more cases of ASCC were diagnosed in PLWH, but they had a higher CD4(+) T cell nadir count. Although more T1–T2 tumours were observed in the second period studied, the difference in tumour size between periods was not statistically significant (p = 0.103). In 23% of patients, HSIL was present before diagnosis (median time to progression: 67.6 months). At the start of the screening programme, four patients in follow‐up were diagnosed with ASCC. In addition, five patients who were not in follow‐up (despite meeting the criteria of the screening programme) were also diagnosed, but at more advanced stages.Conclusions: During the last decade, the cases of ASCC diagnosed in our hospital have not decreased, likely due to the increasing global incidence of this disease, but also to the activity of our screening programme. Nevertheless, four PLWH included in the screening programme were diagnosed at earlier stages of the disease.
- Open Access
- 26 April 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (8) , E489-E491
Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance
- 26 April 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (8) , E489-E491
Open AccessPityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance
- 1 January 2011
- Published by JLE in European Journal Of Dermatology
- Vol. 21 (1) , 120-121
Drug eruption and exacerbation of psoriasis related to bupropion
- 1 January 2011
- Published by JLE in European Journal Of Dermatology
- Vol. 21 (1) , 120-121
Drug eruption and exacerbation of psoriasis related to bupropion